Stanford researchers at the Ferrara Lab have developed a method to select receptor targets for molecular imaging and therapies by applying spatial transcriptomics, proteomics, and machine learning.
Stanford scientists have discovered a DNA methylation signature on circulating tumor DNA (ctDNA) that can distinguish between the aggressive Leiomyosarcoma (LMS) from its benign counterpart leiomyoma (LM) in the uterus.